Lexeo Therapeutics, Inc. announced it has entered into a common stock purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 6,278,905 shares of its common stock at an issue price of $15.13 per share for gross proceeds of $95,000,000 on March 11, 2024. the transaction will include participation from Braidwell LP, Adage Capital Partners LP, RA Capital Management, Surveyor Capital, Eventide Asset Management and Novo Holdings A/S. The transaction is expected to close on March 13, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.63 USD | +3.61% | +7.57% | +23.92% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.92% | 548M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- LXEO Stock
- News Lexeo Therapeutics, Inc.
- Lexeo Therapeutics, Inc. announced that it expects to receive $94.999833 million in funding